Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
Recent development of new immune checkpoint inhibitors has been particularly successfully in cancer treatment, but still the majority patients fail to benefit. Converting resistant tumors to immunotherapy sensitive will provide a significant improvement in patient outcome. Here we identify Mi-2β as...
| Príomhchruthaitheoirí: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formáid: | Journal article |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
Springer Nature
2024
|